Literature DB >> 25694121

MicroRNAs in Breast Cancer: One More Turn in Regulation.

Pilar Eroles, Eduardo Tormo, Begoña Pineda, Estefanía Espin, Ana Lluch.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules that critically regulate the expression of genes. MiRNAs are involved in physiological cellular processes; however, their deregulation has been associated with several pathologies, including cancer. In human breast cancer, differently expressed levels of miRNAs have been identified from those in normal breast tissues. Moreover, several miRNAs have been correlated with pathological phenotype, cancer subtype and therapy response in breast cancer. The resistance to therapy is increasingly a problem in patient management, and miRNAs are emerging as novel therapeutic targets and potential predictive biomarkers for treatment. This review provides an overview of the current situation of miRNAs in breast cancer, focusing on their involvement in resistance and the circulating miRNA. The mechanisms of therapeutic resistance regulated by miRNAs, such as the regulation of receptors, the modification of enzymes of drug metabolism, the inhibition of cell cycle control or pro-apoptotic proteins, the alteration of histone activity and the regulation of DNA repair machinery among others, are discussed for breast cancer clinical subtypes. Additionally, in this review, we summarize the recent knowledge that has established miRNA detection in peripheral body fluids as a suitable biomarker. We review the detection of miRNA in liquid biopsies and its implications for the diagnosis and monitoring of breast cancer. This new generation of cancer biomarkers may lead to a significant improvement in patient management.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25694121     DOI: 10.2174/1389450116666150213114103

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  7 in total

1.  MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1.

Authors:  Jian Yao; Ping Zhang; Jin Li; Wei Xu
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

2.  Down-regulation of MicroRNAs (MiRs) 203, 887, 3619 and 182 Prevents Vimentin-triggered, Phospholipase D (PLD)-mediated Cancer Cell Invasion.

Authors:  Kristen Fite; Julian Gomez-Cambronero
Journal:  J Biol Chem       Date:  2015-11-15       Impact factor: 5.157

3.  Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity.

Authors:  Aristeidis G Telonis; Phillipe Loher; Yi Jing; Eric Londin; Isidore Rigoutsos
Journal:  Nucleic Acids Res       Date:  2015-09-22       Impact factor: 16.971

4.  Illumina Sequencing Reveals Aberrant Expression of MicroRNAs and Their Variants in Whitefish (Coregonus lavaretus) Liver after Exposure to Microcystin-LR.

Authors:  Paweł Brzuzan; Maciej Florczyk; Alicja Łakomiak; Maciej Woźny
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

5.  miR-17 as a diagnostic biomarker regulates cell proliferation in breast cancer.

Authors:  Fangliang Yang; Yuan Li; Lingyun Xu; Yulan Zhu; Haiyan Gao; Lin Zhen; Lin Fang
Journal:  Onco Targets Ther       Date:  2017-01-27       Impact factor: 4.147

6.  The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.

Authors:  Eduardo Tormo; Anna Adam-Artigues; Sandra Ballester; Begoña Pineda; Sandra Zazo; Paula González-Alonso; Joan Albanell; Ana Rovira; Federico Rojo; Ana Lluch; Pilar Eroles
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

7.  Aberrant Expressional Profiling of Known MicroRNAs in the Liver of Silver Carp (Hypophthalmichthys molitrix) Following Microcystin-LR Exposure Based on samllRNA Sequencing.

Authors:  Yiyi Feng; Xi Chen; Junguo Ma; Bangjun Zhang; Xiaoyu Li
Journal:  Toxins (Basel)       Date:  2020-01-09       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.